Not really a death knell but when I have as much riding on MSB as I do, it pays to be listening for the inverse of your investment thesis. The treatment referred to originated in Cuba funnily enough. I would think the FDA would be even more dismissive of that, yet the US firm Equillium is setting up a US based phase 3 study and submitting a U.S. investigational new drug application (IND). they are also planning to evaluate it for GVHD.
Ignore potential competition at your peril I would suggest.
My current thinking for what is worth is that as it only targets T-Cells it will be a less regenerative solution and therefore perhaps a competitor at the margins but I would love to hear from others that seek to research and 'deepen their canyon'.
MSB Price at posting:
$3.22 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)